Inotiv, Inc. Prices Upsized $125 Million Convertible Senior Notes Offering
Inotiv, Inc. (NASDAQ:NOTV) announced the pricing of a $125 million offering of 3.25% convertible senior notes due 2027. This amount is up from the initially planned $110 million. The notes, fully guaranteed by BAS Evansville, Inc., will settle on September 27, 2021. The company expects to net approximately $120.5 million, intended to finance its acquisition of Envigo RMS Holding Corp. The notes will mature on October 15, 2027, and can be converted into shares post-April 15, 2027. Inotiv will also have the option to redeem the notes starting October 15, 2024, under specific conditions.
- Inotiv increased its offering size from $110 million to $125 million.
- Net proceeds from the offering are estimated at approximately $120.5 million.
- Proceeds will be used for the acquisition of Envigo RMS Holding Corp.
- Inotiv's ability to utilize net proceeds depends on the successful completion of the Envigo acquisition.
- The notes will be redeemable if the Envigo acquisition is not closed by June 30, 2022.
WEST LAFAYETTE, Ind., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced the pricing of its offering of
Inotiv estimates that the net proceeds from the offering will be approximately
The notes will be senior, unsecured obligations of Inotiv and will accrue interest at a rate of
The notes will be redeemable, in whole and not in part, for cash at Inotiv’s option at any time on or after October 15, 2024, and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per common share exceeds
If a “fundamental change” (as defined in the indenture for the notes) occurs, then noteholders may require Inotiv to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.
The offer and sale of the notes, the guarantee and any common shares issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any common shares issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
About the Company
Inotiv, Inc. is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.
Forward-Looking Statements
This press release includes forward-looking statements, including statements regarding the completion of the offering, the completion of the pending Envigo acquisition and the expected amount and intended use of the net proceeds. Forward-looking statements represent Inotiv’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to Inotiv’s business, including those described in periodic reports that Inotiv files from time to time with the SEC. Inotiv may not consummate the offering described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Inotiv does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.
Company Contact | Investor Relations | |
Inotiv, Inc. | The Equity Group Inc. | |
Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA | |
(765) 497-8381 | (212) 836-9614 | |
btaylor@inotivco.com | kahl@equityny.com | |
Devin Sullivan | ||
(212) 836-9608 | ||
dsullivan@equityny.com |
FAQ
What is the new offering amount for Inotiv's convertible senior notes?
When will Inotiv's convertible senior notes mature?
What are the intended uses of the proceeds from Inotiv's note offering?
What is the interest rate on Inotiv's convertible senior notes?